Abstract
analysis to be greater than 99.5%. 12.55 (1H each, s, Ph-OH), 7.45 (2H, d, J = 8.8 Hz, H-2''', -6'''), 7.22 (2H, d, J = 8.8 17 Hz, H-2', -6'), 6.92 (1H, d, J = 8.8 Hz, 6.83 (2H, d, J = 8.8 Hz, , 18 6.64 (1H, s, H-8''), 6.29 (1H, d, J = 2.4 Hz, H-6), 6.21 (1H, d, J = 2.4 Hz, H-8), 5.67 19 7 (1H, dd, J = 13.2, 3.0 Hz, H-2''), 3.44 (1H, dd, J = 17.4, 13 .2 Hz, H-3''), 2.96 (1H, dd, 1 J = 17.4, 3.0 Hz, H-3''); 13 C NMR (100 MHz, acetone-d 6 ): δ C 43.7 (C-3''), 80.3 (C-2''), 2 89.9 (C-3), 94.6 (C-6), 100.2 (C-8), 101.1 (C-8''), 103.5 (C-10), 107.5 (C-10''), 115.8 3 (C-3', -5'), 116.2 (C-3''', -5'''), 116.5 (C-6''), 122.1 (C-1'), 129.2 (C-2''', -6'''), 130.1 4 (C-1'''), 132.5 (C-2', -6'), 156.2 (C-9), 156.7 (C-9''), 157.9 (C-4'), 158.9 (C-4'''), 162.4 5 (C-5''), 162.6 (C-7''), 163.1 (C-5), 164.5 (C-7), 166.5 (C-2), 184.2 (C-4), 199.5 (C-4''); 6 system equipped with Diode Array Detector (DAD) model G1315B, and an analytical 12 C18 column (Phenomenex Luna; 5 μm, 150 × 4.6 mm). The injection volume was 5 13 μL, with a gradient of 5% to 100% MeOH in water, at 0.8 mL/min over 30 min. 14 UV-VIS detection was carried at 320 nm. Quantification was based on the measured 15 integration area of the peak of interest, compared to a calibration value from a 16 solution in MeOH of compound 1 between 0.1 -1.0 mg/mL. inhibition assays examined LH-crude, LH-EA, and LH-water fractions at doses of 500, 7 250, 100, 50, and 10 µg/mL, and loniceraflavone and allopurinol (reference 8 compound, purchased from Sigma-Aldrich; Poole, UK; purity > 99.0%) at 9 concentrations of 100, 50, 25, 10, 5, 3, 2, 1 µg/mL. The XOD inhibition was 10 calculated as a percentage, (%) = (1-b/a) × 100, where "a" is the change in absorbance 11
FAB-MS
per min without the sample, and "b" is the change in absorbance per min with the 12 sample. The concentration of samples required to inhibit 50% of XOD activity (IC 50 ) 13 were estimated from the % inhibition versus concentration plot using a linear 14 regression algorithm. 15
Determination of hypouricemic effects in mouse model of hyperuricemia 16
Experiments were performed with the approval of the local Institutional Ethics 17
Committee, and were carried out in accordance with the current guidelines for the 18 care of laboratory animals and the ethical guidelines for investigations of 19 experimental pain in conscious animals [7] . Three-week-old male ICR mice (25-28 g) 1 were purchased from BioLASCO (Taiwan) and the 10 mice in each group were 2 housed in a plastic cage. Mice were housed in the following conditions: temperature 3 25 ± 2°C, relative humidity 55 ± 5%, lighting 06:00-18:00 h, fed with rodent diet 4 (LabDiet 500 l Rodent diet, Purina Mills LLC, St. Louis, MO) and water ad libitum, 5 and were allowed one week to adapt to the environment before testing. The animals 6 were transferred to the laboratory at least 1 h before induction of hyperuricemia by 7 potassium oxonate (PO), a uricase inhibitor [8] . The method used to examine the 8 hyperuricemic effects of LH-EA was as described previously [9] , [10], [11] with slight 9 modifications. Mice were divided into five groups (n = 10): "normal" (no treatment) 10 control group, "PO", "PO + LH-EA300", "PO + LH-EA500", and "PO + Allopurinol". 11
All PO groups were injected intraperitoneally with PO at a dosage of 250 mg/kg 1 h 12 before drug administration to increase serum urate levels. One hour later, the mice in 13 the "PO + LH-EA300" and "PO + LH-EA500" group were orally administrated 300 14 mg/kg and 500 mg/kg of LH-EA; the mice in the "PO + Allopurinol" group were 15 orally administrated 10 mg/kg allopurinol; the mice in the "PO" and "normal" group 16 were administrated saline only. Two hours after PO-induced action, whole blood 17 samples were collected from mice. The blood was allowed to clot for 1 h at ambient 18 temperature and then centrifuged at 3,000 rpm for 5 min to obtain the serum. The 19 serum was stored at -20°C until assayed. The uric acid level was determined by the 1 phosphotungstic acid method, as previously described [12] . 2 3
Statistical analysis 4
Data are expressed means ± SE. Statistical comparisons of the results were made 5 using analysis of variance (ANOVA). Significant differences (* P < 0.05 and ** P < 6 0.01) between the control (untreated) and treated mice were analyzed by Dunnett's 7 test. 8 9
Results

1
In the present study, XOD inhibitory activity of L. hypoglauca extracts was evaluated 2 using a spectrophotometric method ( Table 1) . Both LH-crude and LH-EA inhibited 3 XOD, with 50% inhibition concentration values (IC 50 values) of 48.8 and 35.2 μg/mL, 4 respectively. LH-Water did not show significant XOD inhibition. The most inhibitory 5 fraction, LH-EA, was then examined for any potential effects on serum uric acid 6 levels in oxonate-induced hyperuricemic mice (Fig. 1) . The initial serum uric acid 7 level in mice was 1.84 ± 0.26 mg/dL. Intraperitoneal injection of PO caused a 8 significant increase in serum uric acid , with a maximum serum uric acid level of 5.52 9 ± 0.68 mg/dL, 3 h after injection. After oral administration of LH-EA at doses of 300 10 and 500 mg/kg in PO-induced hyperuricemic mice, the serum uric acid values fell to 11 2.94 ± 0.44 (a reduction of 70.1% from untreated PO mice) and 2.07 ± 0.15 mg/dL (a 12 fall of 93.7%), respectively. Allopurinol, at a dose of 10 mg/kg, reduced the serum 13 uric acid of mice to 1.92 ± 0.02 mg/dL. 
